Guardant Health (NASDAQ:GH) Announces Earnings Results, Misses Estimates By $0.07 EPS

Guardant Health (NASDAQ:GH) released its quarterly earnings data on Thursday. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07), FiscalAI reports. The business had revenue of $281.27 million during the quarter, compared to analysts’ expectations of $269.74 million. During the same period last year, the firm earned ($0.62) EPS. The business’s quarterly revenue was up 39.4% compared to the same quarter last year.

Here are the key takeaways from Guardant Health’s conference call:

• Guardant reported strong top-line momentum with $281M in Q4 (+39% YoY) and $982M for FY2025 (+33% YoY), and guided 2026 revenue of $1.25B–$1.28B (27%–30% growth) toward a $2.2B 2028 target.
• Profitability metrics improved: non‑GAAP gross margin rose to 66%, Reveal cost-per-test fell to under $500, Shield gross margin reached 52% in Q4, and further margin upside is expected from the NovaSeq X transition (~200 bps potential on Guardant360).
• Shield screening is scaling rapidly — ~87,000 tests in 2025 (38,000 in Q4), 93% adherence, an ADLT rate of $1,495, ~300 sales reps and collaborations with Quest and PathGroup — company expects 210k–225k Shield tests in 2026.
• Screening is cash‑intensive: ~ $220M of the company’s $233M 2025 free cash flow burn was driven by Shield, and Guardant expects a similar screening burn (~$220M) in 2026, which delays company‑wide cash flow breakeven until end of 2027 despite the core business being FCF‑positive.

Guardant Health Stock Up 0.5%

GH stock traded up $0.50 during trading on Friday, reaching $106.88. 1,034,376 shares of the company’s stock were exchanged, compared to its average volume of 2,003,629. Guardant Health has a 1-year low of $34.88 and a 1-year high of $120.74. The firm has a market cap of $13.47 billion, a PE ratio of -33.30 and a beta of 1.63. The company’s fifty day moving average price is $106.67 and its 200-day moving average price is $85.53.

Insider Buying and Selling at Guardant Health

In related news, insider Terilyn J. Monroe sold 8,571 shares of the company’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total value of $977,865.39. Following the completion of the sale, the insider owned 20,990 shares of the company’s stock, valued at $2,394,749.10. This represents a 28.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Helmy Eltoukhy sold 90,565 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the transaction, the chief executive officer directly owned 2,047,143 shares in the company, valued at approximately $212,534,386.26. The trade was a 4.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 434,511 shares of company stock valued at $45,580,887. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Guardant Health

Several large investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. bought a new stake in shares of Guardant Health in the 3rd quarter worth approximately $114,421,000. Price T Rowe Associates Inc. MD grew its position in Guardant Health by 33.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after buying an additional 1,414,441 shares during the last quarter. Qube Research & Technologies Ltd increased its holdings in shares of Guardant Health by 124.3% in the third quarter. Qube Research & Technologies Ltd now owns 570,095 shares of the company’s stock valued at $35,620,000 after buying an additional 315,896 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Guardant Health by 205.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 464,905 shares of the company’s stock valued at $47,485,000 after buying an additional 312,783 shares in the last quarter. Finally, Artisan Partners Limited Partnership acquired a new stake in shares of Guardant Health during the 4th quarter valued at $29,657,000. Institutional investors own 92.60% of the company’s stock.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: BTIG raised its price target to $145 and maintained a “buy” rating, implying roughly a mid-30% upside from the recent price — a catalyst for buying interest. Read More.
• Positive Sentiment: Canaccord boosted its target to $135 and kept a “buy” rating, another broker upgrade supporting bullish sentiment. Read More.
• Positive Sentiment: Guardant reported Q4 revenue of $281.3M (up ~39% YoY) and raised FY‑2026 revenue guidance to ~$1.3B vs. consensus near $1.2B — the stronger guidance and revenue beat are the primary drivers of the stock lift. Read More.
• Neutral Sentiment: Company provided detailed earnings/strategy commentary in the Q4 call and slide deck; investors will parse margin path, test volume trends and commercialization cadence for longer‑term valuation impact. Read More. Read More.
• Neutral Sentiment: Robert W. Baird initiated research coverage on GH, which can increase visibility and trading liquidity but doesn’t by itself change fundamentals. Read More.
• Negative Sentiment: EPS missed expectations — reported a $0.50 loss vs. consensus ~$0.43 — a reminder that profitability milestones remain ahead and keeps some investors cautious despite revenue strength. Read More.

Wall Street Analyst Weigh In

GH has been the topic of a number of research analyst reports. Wells Fargo & Company boosted their price objective on shares of Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Evercore set a $105.00 price target on shares of Guardant Health and gave the company an “in-line” rating in a research report on Monday, January 5th. Stifel Nicolaus upped their price target on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday. Mizuho set a $135.00 price objective on Guardant Health in a research note on Friday, January 9th. Finally, Leerink Partners boosted their target price on Guardant Health from $115.00 to $155.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Twenty-two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $109.05.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.